Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Tadalafil

October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Tadalafil

Dosage Form: Tablet

Route: Oral

Strengths: 2.5 mg, 5 mg, 10 mg, 20 mg

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 20 mg
   Subjects: Healthy males
   Additional comments: None

Analyte to measure: Tadalafil in plasma

Bioequivalence based on (90% CI): Tadalafil

Waiver request of in vivo testing: 2.5 mg, 5 mg, and 10 mg strengths based on (i) acceptable bioequivalence study on the 20 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths

NOTE: Tadalafil tablets, 20 mg, and tadalafil tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg are the subject of two separate reference listed drugs (RLDs). Submit a separate abbreviated new drug application (ANDA) referencing each RLD. An applicant may request a waiver of in vivo bioequivalence testing for the ANDA referencing the single 20 mg strength RLD provided that it:

1. Submits acceptable bioequivalence study of this strength in the related ANDA,
2. Cross-references the study submitted in the ANDA for this strength, and
3. Meets the criteria of 21 CFR § 320.22(d) (2). Refer to the most recent version of the guidance for industry on *Variations in Drug Products that May Be Included in a Single ANDA.*[a]

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution. Conduct comparative dissolution testing on 12 dosage units for each of all strengths of the test product and RLD.[1] Specifications will be determined upon review of the ANDA.

Document History: Recommended May 2007; Revised September 2012, October 2017, October 2024

Unique Agency Identifier: PSG_021368

[a] For the most recent version of a guidance, check the FDA guidance website at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.

[1] If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions.*